Stepan Reports Lower First Quarter Results and Announces Dividend
- Net Sales increased 5% to
$477.4 million versus$456.5 million in the prior year. - Net Income was
$13.0 million versus$19.0 million in the prior year. Net Income, excluding deferred compensation, was$12.8 million versus$21.5 million in the prior year. - Diluted EPS was
$0.57 versus$0.83 in the prior year. Diluted EPS, excluding deferred compensation, was$0.56 versus$0.94 in the prior year. - Lower earnings were directly attributable to higher maintenance, energy and freight costs from the adverse weather in
North America and lower North American surfactant demand. Progress on strategic objectives remain on track.
"Despite first quarter net income being
"Despite the disappointing first quarter results, we continue to make progress on our strategic initiatives. Specifically, recent investments in
Summary
($ in thousands, except per share data) |
Three Months Ended March 31 |
||
2014 |
2013 |
% Change |
|
Net Sales |
$ 477,442 |
$ 456,546 |
+ 5 |
Operating Income |
$22,523 |
$28,294 |
- 20 |
Net Income |
13,018 |
19,034 |
- 32 |
Net Income Excluding Deferred Compensation * |
12,767 |
21,516 |
- 41 |
Earnings per Diluted Share |
$ 0.57 |
$ 0.83 |
- 31 |
Earnings per Diluted Share Excluding Deferred Compensation * |
$ 0.56 |
$ 0.94 |
- 40 |
* See Table II for a discussion of deferred compensation plan accounting.
Segment Net Sales
($ in thousands) |
Three Months Ended March 31 |
|||
2014 |
2013 |
% Change |
||
Net Sales |
||||
Surfactants |
$ 335,710 |
$ 339,973 |
-1 |
|
Polymers |
119,107 |
95,998 |
+24 |
|
Specialty Products |
22,625 |
20,575 |
+10 |
|
$ 477,442 |
$ 456,546 |
+5 |
Percentage Change in Net Sales
The increase in net sales was primarily due to higher average selling prices across all three segments partially offset by lower sales volume. This shortfall was predominantly related to the Surfactant segment's North American operations, the region which was significantly impacted by the severe and prolonged winter weather. The shortfall was partially offset by the volume growth in global Polyols and from the incremental volume from the second quarter 2013 acquisition from
Three Months Ended March 31 |
||||
Selling Price |
+ 7 |
|||
Volume |
- 2 |
|||
Foreign Translation |
─ |
|||
Total |
+ 5 |
Segment Sales Volume
- Surfactant sales volume declined 6% for the quarter. Most of this decrease was attributable to the
North America business which experienced a 12% volume decline. Biodiesel volumes accounted for 7% of the North American shortfall. Stepan has filled excess reactor capacity with Biodiesel volumes only when it is economically attractive. During the first quarter, Stepan did not participate in the biodiesel market. The remaining 5% is primarily from U.S. consumer product volume declines due to the adverse weather and lost business as the result of a customer plant closure. Conversely, Enhanced Oil Recovery surfactants and volumes from recent capacity expansions inBrazil andSingapore grew. - Polymer sales volume increased 20% for the quarter. Excluding the impact of the North American polyester resin acquisition from Bayer, growth was 9%. North American polyol volume, used in rigid foam insulation, grew 5% versus prior year. European polyols volume increased 29% largely due to continued market growth in metal panels and C.A.S.E. (Coatings, Adhesives, Sealants and Elastomers). Commodity Phthalic Anhydride volumes in
North America declined 10% due to lower regional market demand and increased competitive activity. - Specialty Products sales volume declined 9% for the quarter on lower food ingredient volumes.
Segment Gross Profit
- Surfactant gross profit declined 21% or
$10.8 million compared to the first quarter of 2013. North American operations accounted for most of the quarterly decline due largely to the negative impact of severe weather that caused higher manufacturing costs at our facilities and reduced demand from customers who also experienced weather related problems. Specifically, maintenance and energy costs at impacted Stepan sites were$3.5 million greater than last year. Furthermore, we incurred higher transportation expenses from carrier delays and sub optimal supply chain movements as a result of weather problems. North American operations also incurred higher depreciation expense of$0.9 million related to the Canadian restructuring initiative approved in the fourth quarter of 2013.Europe andAsia gross profit increased versus prior year. Excluding the negative impact of foreign currency translation,Latin America gross profit improved versus prior year. - Polymer gross profit increased 4% or
$0.7 million versus prior year. The acquisition from Bayer contributed$2.1 million while gross profit from other Polyols increased$0.8 million . Conversely, Phthalic Anhydride was down$2.2 million due to lower volume and higher weather related manufacturing costs. - Specialty Products gross profit increased 20% or
$1.0 million primarily due to higher conjugated linoleic acid (CLA) and pharmaceutical volumes.
Operating Expenses
($ in thousands) |
Three Months Ended March 31 |
|||
2014 |
2013 |
% Change |
||
Selling |
$ 14,146 |
$ 13,728 |
+3 |
|
Administrative - General |
14,679 |
14,418 |
+2 |
|
Administrative - Deferred Compensation (Income)/Expense* |
(248) |
4,933 |
- |
|
Research, development and technical service |
11,924 |
11,327 |
+5 |
|
Total |
$ 40,501 |
$ 44,406 |
-9 |
|
* See Table II for a discussion of deferred compensation plan accounting. |
- Operating expenses, excluding the impact of Administrative – Deferred Compensation Expense, increased 3% for the quarter. The increase was primarily due to costs associated with the new acquisition, increased R&D resources and a higher bad debt provision for a Latin American customer, partially offset by lower bonus expense.
Income Taxes
The effective tax rate increased to 28% for the quarter compared to 25% for the first quarter of 2013. First quarter 2013 was favorably impacted by a number of special one-time credits which did not recur in the current quarter. Specifically, first quarter 2013 benefited from recognizing the retroactive impact of the U.S. research and development credit and other U.S. tax credits. This change was partially offset by the favorable impact of earning a greater percentage of consolidated income outside the U.S. where tax rates remain generally lower than in the U.S.
Selected Balance Sheet Information
The Company's net debt level increased by
($ in millions) |
3/31/14 |
12/31/13 |
3/31/13 |
||
Net Debt |
|||||
Total Debt |
$ 269.6 |
$ 270.6 |
$ 193.9 |
||
Cash |
96.7 |
133.3 |
54.8 |
||
Net Debt |
$ 172.9 |
$ 137.3 |
$ 139.1 |
||
Equity |
564.3 |
553.7 |
494.9 |
||
Net Debt + Equity |
$ 737.2 |
$ 691.0 |
$ 634.0 |
||
Net Debt / (Net Debt + Equity) |
23.5% |
19.9% |
21.9% |
||
The major working capital components are: |
|||||
($ in millions) |
3/31/14 |
12/31/13 |
3/31/13 |
||
Net Receivables |
$ 296.3 |
$ 265.7 |
$ 281.5 |
||
Inventories |
185.6 |
172.4 |
177.4 |
||
Accounts Payable |
(167.8) |
(157.3) |
(150.7) |
||
Total |
$ 314.1 |
$ 280.8 |
$ 308.2 |
Capital expenditures during the quarter were
Stockholder's equity grew to
Outlook
"Lower first quarter earnings were largely due to the adverse winter weather in
Despite this setback, we remain on track in delivering our strategic objectives. We continue to recognize earnings growth from our 2013 acquisition from Bayer and previous capacity expansions in
Surfactant earnings should improve as the year progresses driven by greater Agricultural sales, continued consumer product growth in
Polymers should continue grow. Improving economies in the U.S. and
Dividend Declaration
The Board of Directors of
Conference Call
Supporting Slides
Slides supporting this press release will be made available at www.stepan.com under the Investor Relations center at approximately the same time as this press release is issued.
Corporate Profile
Headquartered in
The common stock is traded on the
Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in
Table I |
|||||||||||||
STEPAN COMPANY Statements of Income For the Three Months Ended March 31, 2014 and 2013 (Unaudited – 000's Omitted) |
|||||||||||||
Three Months Ended March 31 |
|||||||||||||
2014 |
2013 |
% Change |
|||||||||||
Net Sales |
$ 477,442 |
$ 456,546 |
+ |
5 |
|||||||||
Cost of Sales |
414,418 |
383,846 |
+ |
8 |
|||||||||
Gross Profit |
63,024 |
72,700 |
- |
13 |
|||||||||
Operating Expenses: |
|||||||||||||
Selling |
14,146 |
13,728 |
+ |
3 |
|||||||||
Administrative |
14,431 |
19,351 |
- |
25 |
|||||||||
Research, development and technical services |
11,924 |
11,327 |
+ |
5 |
|||||||||
40,501 |
44,406 |
- |
9 |
||||||||||
Operating Income |
22,523 |
28,294 |
- |
20 |
|||||||||
Other Income (Expense): |
|||||||||||||
Interest, net |
(2,957) |
(2,179) |
+ |
36 |
|||||||||
Loss from equity in joint venture |
(1,451) |
(1,413) |
+ |
3 |
|||||||||
Other, net |
(26) |
571 |
NM |
||||||||||
(4,434) |
(3,021) |
+ |
47 |
||||||||||
Income Before Provision for Income Taxes |
18,089 |
25,273 |
- |
28 |
|||||||||
Provision for Income Taxes |
5,081 |
6,276 |
- |
19 |
|||||||||
Net Income |
$ 13,008 |
$ 18,997 |
- |
32 |
|||||||||
Net Loss Attributable to Noncontrolling interests |
10 |
37 |
- |
73 |
|||||||||
Net Income Attributable to Stepan Company |
$ 13,018 |
$ 19,034 |
- |
32 |
|||||||||
Net Income Per Common Share Attributable to Stepan Company |
|||||||||||||
Basic |
$ 0.57 |
$ 0.85 |
- |
33 |
|||||||||
Diluted |
$ 0.57 |
$ 0.83 |
- |
31 |
|||||||||
Shares Used to Compute Net Income Per Common Share Attributable to Stepan Company |
|||||||||||||
Basic |
22,773 |
22,464 |
+ |
1 |
|||||||||
Diluted |
22,964 |
22,887 |
+ |
- |
|||||||||
Table II |
|||||||
Deferred Compensation Plan |
|||||||
The full effect of the deferred compensation plan on quarterly net income was $2.5 million of expense versus $1.3 million of expense last year. The accounting for the deferred compensation plan results in operating income when the price of Stepan Company common stock or mutual funds held in the plan fall and expense when they rise. The Company also recognizes the change in value of mutual funds as investment income or loss. The quarter end market prices of Stepan Company common stock are as follows: |
|||||||
2014 |
2013 |
2012 |
|||||
3/31 |
12/31 |
9/30 |
6/30 |
3/31 |
12/31 |
||
64.56 |
$65.63 |
$57.73 |
$55.61 |
$63.10 |
$55.54 |
The deferred compensation income statement impact is summarized below: |
|||
($ in thousands) |
Three Months Ended March 31 |
||
2014 |
2013 |
||
Deferred Compensation |
|||
Administrative Income/(Expense) |
$ 248 |
$ (4,933) |
|
Other, net – Mutual Fund Income |
157 |
930 |
|
Total Pretax |
405 |
(4,003) |
|
Total After Tax |
$ 251 |
$ (2,482) |
|
Reconciliation of non-GAAP net income: |
|||
($ in thousands) |
Three Months Ended March 31 |
||
2014 |
2013 |
||
Net income excluding deferred compensation |
$ 12,767 |
$ 21,516 |
|
Deferred compensation plan Income/(Expense) |
251 |
(2,482) |
|
Net income as reported |
$ 13,018 |
$ 19,034 |
|
Reconciliation of non-GAAP EPS: |
|||
Three Months Ended March 31 |
|||
2014 |
2013 |
||
Earnings per diluted share excluding deferred Compensation |
$ 0.56 |
$ 0.94 |
|
Deferred compensation plan income/(expense) |
0.01 |
(0.11) |
|
Earnings per diluted share |
$ 0.57 |
$ 0.83 |
|
The Company believes that certain non-GAAP measures, when presented in conjunction with comparable GAAP (Generally Accepted Accounting Principles) measures, are useful because that information is an appropriate measure for evaluating the Company's operating performance. Internally, the Company uses this non-GAAP information as an indicator of business performance, and evaluates management's effectiveness with specific reference to these indicators. These measures should be considered in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. |
Table III |
||||
Effects of Foreign Currency Translation |
||||
The Company's foreign subsidiaries transact business and report financial results in their respective local currencies. As a result, foreign subsidiary income statements are translated into U.S. dollars at average foreign exchange rates appropriate for the reporting period. Because foreign exchange rates fluctuate against the U.S. dollar over time, foreign currency translation affects period-to-period comparisons of financial statement items (i.e. because foreign exchange rates fluctuate, similar period-to-period local currency results for a foreign subsidiary may translate into different U.S. dollar results). Below is a table that presents the impact that foreign currency translation had on the changes in consolidated net sales and various income line items for the first quarter: |
||||
Three Months Ended March 31 |
Increase (Decrease) |
(Decrease) Due to |
||
(In millions) |
2014 |
2013 |
||
Net Sales |
477.4 |
456.5 |
20.9 |
(1.7) |
Gross Profit |
63.0 |
72.7 |
(9.7) |
(0.4) |
Operating Income |
22.5 |
28.3 |
(5.8) |
(0.3) |
Pretax Income |
18.1 |
25.3 |
(7.2) |
─ |
Table IV |
|||
Stepan Company |
|||
2014 March 31 |
2013 December 31 |
||
ASSETS |
|||
Current Assets |
$ 613,485 |
$ 608,550 |
|
Property, Plant & Equipment, Net |
495,123 |
494,042 |
|
Other Assets |
65,925 |
64,610 |
|
Total Assets |
$ 1,174,533 |
$ 1,167,202 |
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|||
Current Liabilities |
$ 269,162 |
$ 268,993 |
|
Deferred Income Taxes |
18,935 |
20,616 |
|
Long-term Debt |
234,565 |
235,246 |
|
Other Non-current Liabilities |
87,576 |
88,606 |
|
Total Stepan Company Stockholders' Equity |
562,873 |
552,286 |
|
Noncontrolling Interest |
1,422 |
1,455 |
|
Total Liabilities and Stockholders' Equity |
$ 1,174,533 |
$ 1,167,202 |
SOURCE
Scott D. Beamer, (847) 446-7500